Clinical Effect of alpha 1D/A adrenoceptor inhibitor naftopidil on Benign Prostatic Hyperplasia: An International Prostate Symptom Score and King's Health Questionnaire assessment

International Journal of Urology

Volumn 15, Issue 8, 2008, Pages 709-715

  Awa, Yusuke ^a,b   Suzuki, Hiroyoshi ^a,b   Hamano, Satoshi ^b   Okano, Tatsuya ^b   Sakurayama, Yuri ^b   Ohki, Takemasa ^b   Egoshi, Ken Ichi ^b   Ota, Sho ^b   Mori, Ikuo ^b   Ichikawa, Tomohiko ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Chiba Continence Research Society   (Japan)

Author keywords

1 blocker; Benign prostatic hyperplasia; IPSS; KHQ; Quality of life

Indexed keywords

NAFTOPIDIL;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE INDEX; QUESTIONNAIRE; TREATMENT DURATION; URINE FLOW RATE; UROFLOWMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; NAPHTHALENES; PIPERAZINES; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 49549084837     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02097.x     Document Type: Article

References (17)

1. Homma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996 3 : 267 73.
2. Haltbakk J, Hanestad BR, Hunskaar S et al. Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms. BJU Int. 2003 91 : 380 8.
3. Suzuki H, Yano M, Awa Y et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. Int. J. Urol. 2006 13 : 1202 6.
4. Kelleher CJ, Kreder KJ, Pleil AM et al. Long-term health-related quality of life of patients receiving extended-release Tolterodine for overactive bladder. Am. J. Manag. Care. 2002 8 (19 Suppl S616 S630.
5. Homma Y, Ando T, Yoshida M et al. Validation of the Japanese version of QOL questionnaires for urinary incontinence. NBS 2002 13 : 247 57.
6. Takei R, Ikegaki I, Shibata K et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn. J. Pharmacol. 1999 79 : 447 54.
7. Malloy BJ, Price DT, Price RR et al. Alpha1-adrenergic receptor subtypes in human detrusor. J. Urol. 1998 160 : 937 43.
8. Barry MJ, Fowler FJ Jr., O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol. 1992 148 : 1549 57.
9. Donovan JL, Badia X, Corcos J et al. Symptom and quality of life assessment. Incontinence: 2nd International Consultation on Incontinence. 2002 267 316.
10. Suzuki H, Akakura K, Igarashi T et al. Clinical usefulness of serum anti-p53 antibodies for prostate cancer detection: A comparative study with PSA parameters. J. Urol. 2004 171 : 182 6.
11. Suzuki H, Komiya A, Kamiya N et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006 67 : 131 6.
12. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn. 2002 21 : 167 78.
13. Kelleher CJ, Cardozo LD, Khullar V et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. 1997 104 : 1374 9.
14. Uemura S, Homma Y. Reliability and validity of King's Health Questionnaire in patients with symptoms of overactive bladder with urge incontinence in Japan. Neurourol. Urodyn. 2004 23 : 94 100.
15. Ikemoto I, Kiyota H, Ohishi Y et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int. J. Urol. 2003 10 : 587 94.
16. 1A/D-adrenoceptor blocker(naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int. J. Urol. 2006 13 : 15 20.
17. 1- adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006 97 : 747 51.